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ABSTRACT
Translation termination in eukaryotes is governed
by the concerted action of eRF1 and eRF3 factors.
eRF1 recognizes the stop codon in the A site of
the ribosome and promotes nascent peptide chain
release, and the GTPase eRF3 facilitates this
peptide release via its interaction with eRF1. In
addition to its role in termination, eRF3 is involved
in normal and nonsense-mediated mRNA decay
through its association with cytoplasmic poly(A)-
binding protein (PABP) via PAM2-1 and PAM2-2
motifs in the N-terminal domain of eRF3. We have
studied complex formation between full-length
eRF3 and its ligands (GDP, GTP, eRF1 and PABP)
using isothermal titration calorimetry, demons-
trating formation of the eRF1:eRF3:PABP:GTP
complex. Analysis of the temperature dependence
of eRF3 interactions with G nucleotides reveals
major structural rearrangements accompanying
formation of the eRF1:eRF3:GTP complex. This is
in contrast to eRF1:eRF3:GDP complex formation,
where no such rearrangements were detected.
Thus, our results agree with the established active
role of GTP in promoting translation termination.
Through point mutagenesis of PAM2-1 and PAM2-
2 motifs in eRF3, we demonstrate that PAM2-2, but
not PAM2-1 is indispensible for eRF3:PABP complex
formation.
INTRODUCTION
Translation termination occurs when a stop codon enters
the ribosomal A site and signals for polypeptide chain
release from the peptidyl-tRNA located in the ribosomal
P site. In eukaryotes, this process is facilitated by two
proteins: eRF1 (1) and eRF3 (2). eRF1 is the class I
release factor that recognizes the stop codon in the
A site and stimulates nascent peptide chain release.
The class II release factor eRF3 is a GTPase, and it
facilitates peptide release by eRF1.
Complex formation between eRF3 and eRF1 promotes
GTP binding to eRF3 (3–6), with eRF1 acting as GTP
Stabilizing Factor (GSF) (7). GTP hydrolysis on eRF3 is
activated by the ribosome and eRF1, and is required for
fast and eﬃcient termination of translation in eukaryotes
(8,9).
In addition to its role in termination, eRF3 is involved
in normal and Nonsense-Mediated mRNA Decay (NMD)
via two diﬀerent pathways: through its association with
cytoplasmic poly(A)-binding protein (PABP) (10–13) and
Upf1 (14,15). The former interaction is considered as
a regulator of PABP interactions with the 30-poly(A)
tail of mRNAs, suggesting that eRF3 may also play an
important role in the degradation of mRNAs and/or the
regulation of translation eﬃciency mediated through ini-
tiation factors (11,16). Our current understanding of the
eRF3 GTPase cycle regulation via interactions with these
factors is far from complete. Complex formation between
eRF3 and PABP, as well as eRF3 and Upf1, is GTP/GDP
insensitive, as opposed to the eRF1/eRF3 interaction (15).
Quantitative data regarding eRF3 interactions with PABP
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the interplay between eRF1, G nucleotides and PABP
binding to eRF3.
Mammalian eRF3 is divided into at least two regions:
the N- and C-terminal regions. The C-terminal domains
are homologous to those of elongation factor EF1A,
and both proteins are close relatives in the translational
GTPase (trGTPase) superfamily (17). The C-terminal
region of eRF3 is responsible for translation termination
activity and is essential for viability (2,18). In contrast, the
N-terminal domain shows little conservation (17,19,20)
and is dispensable for the termination process. However,
it has been demonstrated to be important for binding to
PABP (10–13) as well as several other factors, e.g. Sla1
(21) and Itt1 (22). Interaction with PABP, which is the
focus of the present study, is mediated by a PAM2
sequence motif in the eRF3 N-terminal domain (23,24).
Importantly, the majority of the available biochemical
data on the eRF3 GTPase cycle were obtained using an
eRF3 variant lacking the N-domain (3–6), which could
potentially lead to severe artifacts. Based on the available
X-ray structure of the N-terminally deleted eRF3 (25), it
has been suggested that the N-domain may block the
eRF1-binding site thus potentially regulating eRF1 and
GTP binding (26). Preparation of full-length eRF3 using
an Escherichia coli over-expression system has never been
achieved, although the truncated version of the factor
was ﬁrst puriﬁed almost 15 years ago (2). Over-expression
in insect cells was successful, but the yields obtained
precluded detailed biochemical investigations (27). Thus,
rigorous biochemical investigations of the eRF1:eRF3:
PABP:G nucleotides interaction network have so far
been impossible.
In order to overcome this problem, we constructed an
over-expression construct based on a modern protein
expression vector pETM-20, which allowed over-
expression and puriﬁcation of the full-length eRF3.
We have for the ﬁrst time studied complex formation
between full-length eRF3 and its ligands (GDP, GTP,
eRF1 and PABP) using Isothermal Titration Calorimetry
(ITC) and investigated the temperature dependence of
these interactions. We have revealed the structural
rearrangements in the interacting partners via thorough
thermodynamic analysis. Through sequence analysis
of the eRF3 N-domain, we demonstrate that the two
overlapping PAM2 minidomains in human eRF3 (23)
that are responsible for the eRF1–PABP complex forma-
tion, are present in a wide distribution of metazoa. Using
point mutagenesis we studied the role of both of the motifs
(PAM2-1 and PAM2-2) in eRF3:PABP interaction, and
showed that PAM2-2, but not PAM2-1, as was suggested
earlier (28), is indispensible for complex formation. This
provides a tool to dissect the roles of eRF3 in translation
termination and NMD.
MATERIALS AND METHODS
Cloning and mutagenesis of human eRF3a
The full-length cDNA encoding eRF3a (GSPT1, sequence
corresponding to NCBI GI number 119605536) was fused
with the 109aa Trx Tag
TM thioredoxin protein followed
by 6His for aﬃnity puriﬁcation. The mutagenesis pro-
cedure was performed according to the PCR-based
‘megaprimer’ method (29). Two rounds of PCR were per-
formed with the same PCR mixture. For all the mutants,
the direct primer 50-ATCCCATGGATCCGGGCAGTG
GC-30 (the NcoI site underlined) together with one of
the reverse primers for these mutants were used in the
ﬁrst round of PCR. In the second round the ‘megaprimer’
synthesized in the ﬁrst round served as the direct primer
together with the reverse primer 50-GCGCTCGAGTTAG
TCTTTCTCTGGAACCAGTTTC-30 (XhoI site
underlined). The resulting 1914bp PCR product was
puriﬁed in 1% agarose gel using a DNA extraction kit
(GE Healthcare), hydrolyzed with NcoI and XhoI,
ligated with pETM-20 plasmid and treated with the
same endonucleases. The ligated mixture was used for
the transformation of E. coli, strain Top10. The cloned
DNAs were sequenced and appropriate clones were used
for the expression of the mutant eRF3a variants.
Bioinformatics
eRF3 sequences from a wide sample of eukaryotes were
retrieved from trGTPbase, a database of translational
GTPases (GCA, http://www.GTPbase.org.uk). Multiple
sequence alignment was carried out with MAFFT
v6.234b with strategy L-INS-I (30). The data set was
reduced to a representative set of sequences that showed
homology in the N-terminal domain in the region of the
PAM2 minidomain. The alignment was adjusted by eye,
using Bioedit, http://www.mbio.ncsu.edu/BioEdit/bioedit
.html (31). Consensus sequences were computed with the
Python program ConsensusFinder (GCA).
Protein expression and puriﬁcation
Human 6His eRF1 was expressed and puriﬁed according
to (8) with minor modiﬁcations.
For preparation of the full-length (FL) human eRF3
BL21 cells were transformed with the pETM-20
eRF3FL plasmid and grown in 2xLB, supplemented
with 100mg/ml ampicillin at 37 C until the OD reached
0.6 (A600nm). Cells were then transferred to ice for
30min, and induced with IPTG at a ﬁnal concentration
of 0.25mM. An additional 50mg/ml ampicillin was added
and induced cells were grown at 20 C for 18h and then
harvested.
Cells were lyzed by sonication in the buﬀer containing
70mM Tris pH 8.0, 10% glycerol, 30mM KCl, 1% Triton
X100, 1mM beta-mercaptoethanol (BME), 1mM PMSF,
1g/l lyzosyme and 0.2g/l DNAse A. Cell debris was
removed by centrifugation at 18krpm for 20min, two
times, and cleared lyzate was loaded onto a 5ml NiNTA
FF column (GE Healthcare). Bound column was washed
with wash buﬀer containing 50mM Tris pH 7.5, 10%
glycerol, 1mM BME and consecutively decreasing
amounts of KCl: 2M (20 CV), 0.8M (5 CV) and 0.1M
(5 CV). The protein was step-eluted with the wash buﬀer
containing 0.1M KCl and 100mM imidazole.
Eluted protein was further puriﬁed on a 5ml Resource
Q FF column (GE Healthcare) using a linear gradient
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8.0, 10% glycerol, 1mM BME. The eRF3 peak was col-
lected and dialyzed overnight with TEV protease added to
eRF3 in 1:25 ratio against the storage buﬀer containing
10% glycerol, 1mM DTT, 25mM potassium phosphate
(pH 7.4), 0.1M KCl and 2mM MgCl2. The TEV protease
and the cleaved oﬀ Trx tag were removed by incubation
with NiNTA–agarose (Qiagen), and puriﬁed protein was
used for the experiments directly without freezing.
Human 6His PABP was over-expressed and puriﬁed in
the same way as 6His eRF3, except for the absence of the
TEV protease treatment.
ITC
The thermodynamic parameters of eRF3 binding to
eRF1, G nucleotides and PABP were measured using a
MicroCal VP-ITC and AutoITC instruments (MicroCal,
Northampton, MA) as previously described (5).
Experiments were carried out in phosphate buﬀer
(25mM K2HPO4, 10% glycerol, 1mM DTT and 0.1M
KCl), at pH 7.5. Ligands of 15-ml aliquots were injected
from a 296-ml syringe into the 1.42-ml cell containing
protein solution to achieve a complete binding isotherm.
Protein concentration in the cell ranged from 4 to 15mM
and ligand concentration in the syringe ranged from 40 to
300mM. The heat of dilution was measured by injecting
the ligand into the buﬀer solution or by additional
injections of ligand after saturation; the values obtained
were subtracted from the heat of reaction to obtain the
eﬀective heat of binding. The resulting titration curves
were ﬁtted using MicroCal Origin software, assuming
one set of sites. Aﬃnity constants (Ka), binding
stoichiometry and enthalpy variations (H) were deter-
mined by a non-linear regression ﬁtting procedure.
Consequently, the Gibbs energy (G) and the entropy
variations (S) were calculated from the relation
G= RTlnKa=H TS.
To investigate protonation eﬀects on eRF3 interactions
with eRF1, experiments were performed in two buﬀers,
phosphate (see above) and Tris (50mM Tris–HCl, 10%
glycerol, 5mM b-mercaptoethanol and 0.15M KCl) with
diﬀerent ionization enthalpy (1 versus 11kcal/mol) as
described (5).
RESULTS
Preparation of full-length human eRF3
Numerous previously unsuccessful attempts of over-
expression of the full-length eRF3 without stabilizing
fusion proteins were undertaken by us and others, all
being foiled by low levels of soluble protein. Therefore
we took another approach, overexpressing eRF3 as
a fusion protein in pETM-20 vector (32) (EMBL,
Heidelberg, Germany) with subsequent removal of the
thioredoxin+6His tag by TEV protease cleavage
(see Materials and methods section for details). The
thioredoxin fusion considerably improved protein stability
and solubility and was crucial for full-length eRF3 over-
expression. TEV cleavage was speciﬁc and resulted in the
production of a single band at apparent molecular weight
of about 85kDa (Figure 1), similarly to eRF3 over-
expressed in insect cells using viral vectors (27).
Eﬀect of N-domain of eRF3 on binding to eRF1, GDP and
GTP
In our previous work, we determined the thermodynamic
parameters of interactions of an N-domain deleted variant
of eRF3 (eRF3Cp) with eRF1, GDP and GTP (3–5).
However, the eﬀects of the N-domain on eRF3 GTPase
function were not investigated. Here we used isothermal
titration calorimetry to measure the aﬃnities to G
nucleotides and eRF1 for full-length eRF3.
The results are summarized in Tables 1 and 2, and a
typical set of ITC data for binding of eRF1 and GDP to
eRF3 and GTP to eRF3:eRF1 complex at 25 C is shown
in Figure 2A–C. The binding curves were ﬁtted assuming
one set of sites. Our quantitative results demonstrate that
interactions among eRF1, eRF3 and G nucleotides
are weakly aﬀected by the presence of the N-domain.
For free eRF3, we observed somewhat increased (four
times) aﬃnity to GDP in comparison with the eRF3Cp
variant, and for the eRF3:eRF1 complex, aﬃnities to GTP
(Kd=0.6mM) and GDP (Kd=1.1mM) changed only
slightly.
Enthalpic and entropic partitions of the interaction
energetics were similar for full length eRF3 and the Cp
variant only in the case of eRF1 binding, and diﬀered
considerably in the case of GTP and GDP binding to
the eRF1:eRF3 complex (Table 1). In this case, enthalpic
contribution to overall free-energy diminishes while the
enthropic contribution increases (Table 1), compensating
for the enthalpic change and resulting in virtually
unperturbed G (or equilibrium constant). Thus, despite
the fact that the N-terminal region of eRF3 is not essential
for G-nucleotide binding, it dramatically changes the
thermodynamic proﬁle of the interaction. Changes in the
binding enthalpy and entropy in opposite directions upon
system perturbation, such as deletion of a domain in the
Figure 1. SDS–PAGE analysis of the full-length human eRF3
preparation. The protein was initially expressed as a fusion with a
thioredoxin+6His tag (Trx eRF3wt), which was speciﬁcally cleaved
oﬀ by TEV protease, resulting in full-length eRF3wt.
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known as ‘enthalpy–entropy compensation’ (33).
Eﬀect of temperature on eRF3 binding to GDP, GTP
and eRF1
The binding of GDP, GTP and eRF1 to eRF3 was studied
at six diﬀerent temperatures from 4 to 37 C, and the
results are summarized in Tables 2 and 3.
There is almost no eﬀect of the temperature on the
Kd-value for GDP binding to eRF3, similarly to what
we observed earlier for another trGTPase, EF-G (34).
On the other hand, aﬃnity of eRF3 to GDP in the
eRF1:eRF3 complex decreased 4-fold when the tempera-
ture increased from 4 C( Kd=0.33mM) to 37 C
(Kd=1.4mM). The Kd-value for GTP binding to the
eRF1:eRF3 complex, in contrast, decreased 4-fold when
Table 2. Thermodynamic parameters of eRF3 binding to eRF1, GDP and GTP at diﬀerent temperatures, pH 7.5 determined by isothermal
titration calorimetry
a
Sample Ligand T ( C) K‘ 10
 5 (M
 1) Kd (mM) H (kcal/mol) TS (kcal/mol) G (kcal/mol)
eRF3 GDP 4 23 0.44  4.9 3.16  8.06
10 22 0.46  5.2 3.01  8.21
15 23 0.44  5.46 2.92  8.38
25 20 0.50  6.03 2.57  8.59
30 19 0.53  6.3 2.40  8.70
37 20 0.50  6.72 2.22  8.94
eRF3 eRF1 4 21 0.48  0.97 7.04  8.01
10 23 0.44  2.9 5.34  8.24
15 27 0.37  3.92 4.56  8.48
25 44 0.23  7.1 1.96  9.06
30 51 0.20  8.1 1.20  9.30
37 93 0.11  10.4  0.52  9.88
eRF1:eRF3 GDP 4 30 0.33  3.96 4.24  8.20
10 20 0.50  4.46 3.70  8.16
15 12 0.83  4.97 3.05  8.02
25 9.3 1.1  5.83 2.31  8.14
30 9.1 1.1  6.44 1.82  8.26
37 7.4 1.4  7.10 1.22  8.32
eRF1:eRF3 GTP 4 5.1 2.0 31.3 38.53  7.23
10 9.8 1.0 24.4 32.16  7.76
15 20 0.5 17.38 25.68  8.30
25 19 0.52 3 11.56  8.56
30 20 0.5  7.16 1.58 8.74
37 19 0.52  16  7.09  8.91
aSymbols, abbreviations and all other details are given in the Table 1 footnote.
Table 1. Thermodynamic parameters of eRF3 binding to eRF1, GDP, GTP and PABP at 25 C, pH 7.5 determined by isothermal titration
calorimetry
a
Sample Ligand K‘ 10
 5b (M
 1) Kd
c (mM) H
d (kcal/mol) TS (kcal/mol) G (kcal/mol)
eRF3 GDP 20 (5.6) 0.5 (1.9)  5.7 ( 9.2) 2.9 ( 1.4)  8.6 ( 7.8)
eRF3 eRF1 44 (14) 0.2 (0.7)  6.1 ( 7.2)
e 3.0 (1.2)  9.1 ( 8.4)
eRF3:GDP eRF1 11 (49) 0.9 (0.2)  10.8 ( 3.1)
e  2.6 (6.0)  8.2 ( 9.1)
eRF1:eRF3 GDP 9.3 (5.1) 1.1 (2.0)  5.8 ( 11.8) 2.3 ( 4.0)  8.1 ( 7.8)
eRF1:eRF3 GTP 18 (20) 0.6 (0.5) 3.0 ( 2.2) 11.5 (6.4)  8.5 ( 8.6)
eRF3
f PABP 14 0.7  30.3  21.9  8.4
eRF1:eRF3 PABP 14 0.7  26.3  17.9  8.4
eRF3:PABP eRF1 32 0.3  4.6 4.3  8.9
eRF1:eRF3:PABP GTP 16 0.6 3.2 11.7  8.5
eRF3:PABP GDP 15 0.6  5.9 2.5  8.4
eRF1:eRF3:PABP GDP 14 0.6  4.6 3.8  8.4
eRF3(KAKA)
f PABP 11 0.9  9.2  0.9  8.3
eRF3(AAK) PABP nd
g
eRF3(AAKAA) PABP nd
aIn the brackets are the data for eRF3Cp, according to ref. (5). All measurements were performed in phosphate buﬀer (25mM K2HPO4,
10% glycerol, 1mM DTT and 0.1M KCl).
bThe standard deviation did not exceed ±20%.
cCalculated as 1/K‘.
dThe standard deviation did not exceed ±8%.
eH was calculated taking into account the eﬀect of protonation (see ‘Materials and Methods’ section).
fStoichiometry of the interaction is 1 PABP to 2 eRF3 molecules, and in all other cases it is close to unity.
gnd—not detected.
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(Kd=0.5mM), after which the change in the aﬃnity with
temperature was small (Table 2). The Kd-value for eRF1
binding to eRF3 increased 4.5-fold from 0.48mM( 4  C) to
0.11mM (37 C).
Plotting the enthalpy of the interaction versus temper-
ature, or entropy versus the logarithm of temperature, we
obtained heat capacity change (Cp) values for eRF3
interactions with G nucleotides and eRF1 both for the
full-length eRF3 and for the N-terminally truncated Cp
variant (Figure 3, Table 3). The results are similar for
the two eRF3 versions: binding of eRF1 was characterized
by Cp of  281 and  270cal mol
 1K
 1 for eRF3 and
eRF3Cp, respectively, and GTP binding to eRF1:eRF3
complex was characterized by an immense Cp of
 1470 and  850cal mol
 1K
 1 for eRF3 and eRF3Cp,
respectively. GDP binding both to eRF3 alone and
eRF1:eRF3 complex had low Cp of  55 and
 96cal mol
 1K
 1, respectively.
Changes in the heat capacity are believed to reﬂect the
change in the solvent accessible area (SAA) during the
process (35), and a wealth of available experimental
data has been analyzed providing an empirical formula
connecting the change in Cp and the change in solvent
accessible area: Cp=0.27Aaromatic+0.4Anon-
aromatic, where Aaromatic and Anon-aromatic are the
protected areas due to aromatic and non-aromatic
amino acids in A ˚ 2, respectively (36). This formula was
used to translate the Cp values into the SAA change
estimates (Table 3).
Bioinformatic analysis of the eRF3 N-domain
The eRF3 N-domain was excluded from previous compar-
ative sequence analyses due to its high variability in
sequence and length in both eRF3 and its close relative
Hbs1p (17,19,20). However, a survey of the distribution of
the Pfam HMM domain PAM2 (37) in the Swiss-Prot/
TrEMBL databases suggests that within the largely
unconserved N-domain, this short (15 amino acids)
minidomain is conserved in eRF3 from a wide distribution
of metazoa (24).
eRF3 has been found to contain two overlapping
PAM2 minidomains (PAM2-1 and PAM2-2) in humans
(23). However, it is not known how widespread these dual
minidomains are. Therefore, we have investigated the
distribution of both PAM2 minidomains of eRF3 across
Figure 2. ITC titration curves (upper panel) and binding isotherms (lower panel) for eRF3 interaction with eRF1 (A), GDP (B) and PABP (D) and
eRF3:eRF1 complex interaction with GTP (C)a t2 5  C in phosphate buﬀer (pH 7.5).
Table 3. Heat capacity changes and solvent-accessible surface area for eRF3 binding to eRF1, GDP and GTP
a
Sample Ligand CH
p (calmol
 1K
 1) CS
p (calmol
 1K
 1) SAAmin
b (A ˚ 2) SAAmax
b (A ˚ 2)
eRF3 GDP  55  39 137.5 203
eRF3 eRF1  281  237 702.5 1040
eRF3Cp eRF1  270  235 675 1000
eRF1:eRF3 GDP  96  100 240 355.5
eRF1:eRF3 GTP  1470  1480 3675 5444
eRF1:eRF3Cp GTP  850  805 2125 3148
aHeat capacity changes were obtained as d(H)/dT and d(S)/d(lnT).
bChanges in SAA were estimated using the following formula: Cp=0.27Aaromatic+0.4Anon-aromatic, where Aaromatic and Anon-aromatic are the
protected areas due to aromatic and non-aromatic amino acids in A ˚ 2, respectively (36). SAAmin and SAAmax are calculated assuming that all the
changes are conferred by non-aromatic and aromatic residues, respectively.
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of eRF3 (C and G) are closely related to those of other
eukaryotic trGTPases Hbs1p, eEF1A and Ski7p.
However, PAM2-like motifs are only found in eRF3. To
investigate conservation of the PAM2 minidomains
in eRF3, sequences from a wide sample of eukaryotes
were aligned and reduced to a representative data
set that showed homology in the PAM2 region of the
N-terminal domain. Seventy percent consensus sequences
were generated for two subsets of this data set: a metazoan
subset and a fungal subset (Figure 4).
Within eRF3, we have found two adjacent conserved
PAM2 motifs across all sampled metazoans, with the
possible exception of insects, where PAM2-1 appears
unconserved (Tribolium castaneum, Apis mellifera and
Drosophila melanogaster). The metazoan consensus
motifs for PAM2-1 and PAM2-2 are repectively,
‘LNV.AKPFVP’ and ‘NVhAAEFVPSF’, where upper-
case letters indicate amino acid conservation of over
70% (Figure 3). At deeper levels than Metazoa,
conservation becomes ambiguous. The predicted eRF3
protein of the choanoﬂagellate Monosiga brevicollis lacks
the N-domain, however, conceptual translation of the
genomic sequence (NCBI GI number 163776760)
identiﬁes a miss-annotated start codon that extends the
predicted protein by 80 residues (not shown). This exten-
sion shows no clear homology to other eRF3s, however it
does contain a ‘LNV’ tripeptide, which may correspond to
the ‘LNV’ of the PAM2-1 consensus. PAM2-1 also
appears to be present in the amoebozoan Dictyostelium
discoidium, with six of the nine conserved PAM2-1
residues present in the corresponding region in this
organism (Figure 4). While homology in the PAM2
region appears to be present in some fungi, only the
asparagines of PAM2-1/2 residues are speciﬁcally
conserved. This region of possible homology could not
be identiﬁed in Saccharomyces cerevisiae, suggesting that
in this organism PABP binding to eRF3 is mediated by an
alternative molecular interface.
The alignment has revealed other interesting conserved
features of the extreme N-terminus of eRF3. Runs of
Glycine and Serine are common in mammalian eRF3
(Figure 3). In organisms with both eRF3a and eRF3b,
the extreme N-terminal Glycine runs are predominately
in the eRF3a form. Additionally, a conserved patch with
consensus ‘sdsAPD.WdQ.d’ is present in many
metazoans, with a possibly homologous region in fungi
with consensus ‘dSWEDd.a.QDe’ (Figure 4). As with
PAM2, this conserved patch could not be identiﬁed in
S. cerevisiae. The speciﬁc functions of these additional
N-terminal regions are currently unknown.
Interactions of eRF3 with PABP
Using the full-length eRF3 variant we quantitatively
characterized eRF3 interactions with PABP using ITC
(Figure 2D, Table 1). Our data suggest that complex for-
mation between eRF3 and PABP does not aﬀect eRF3
interactions with G nucleotides and eRF1 (Table 1),
both in the case of PABP binding to eRF3 and to the
eRF1:eRF3 complex. The Cp variant lacking the
N-domain was unable to bind PABP (data not shown).
Current results are in contradiction with our previous
report (3), where we suggested possible inhibitory eﬀect
of PABP on GTP binding by eRF3. However, in the
previous work no systematic analysis was done, which
necessitated the current study. This data suggest that
eRF3Cp can serve as a valid model for investigation of
the eRF3:eRF1:GTP interactions in the framework of ter-
mination mechanisms, but is not valid for studying eﬀects
associated with PABP binding.
In order to map the eRF3:PABP interaction, we per-
formed mutagenesis of the conserved residues in PAM2-1
and PAM2-2 motifs. We constructed three mutants,
namely a KAKA mutant disrupting the PAM2-1 motif
and AKA and AAKAA mutants disrupting the PAM2-2
motif (Figure 4). The KAKA mutant was created earlier
and was claimed to disrupt the eRF3:PABP interaction as
judged by western blot (28). Analysis of the mutant
variants in the current study demonstrates that the inter-
action between PABP and both PAM2-2 mutants (AKA
Figure 3. Temperature dependence of entropy and enthalpy of eRF3
interactions with eRF1 (triangles) and GDP (circles) and eRF3:eRF1
complex with GDP (inverted triangle) and GTP (square). (A) Enthalpy
of binding as a function of the temperature ( C) at pH 7.5. (B) Entropy
of binding as functions of the logarithm of the temperature (K) at pH
7.5. Experimental errors bars were not exceeding the size of the
symbols, thus are not presented on the graph.
Nucleic AcidsResearch, 2010, Vol.38,No. 2 553and AAKAA) was non-detectable, suggesting absolute
necessity of the AKA motif for the interaction.
However, the PAM2-1 KAKA mutant retained
somewhat compromised aﬃnity to PABP (Table 1). The
equilibrium dissociation constant remained almost
unaltered (0.7mM for eRF3wt versus 0.9mM for the
KAKA mutant), but the energetics of the interaction
were altered. In the case of the wild type, protein interac-
tion is characterized by enthalpy of  30kcal/mol, whereas
the KAKA mutant has three times lower enthalpy of
 9kcal/mol. This more labile interaction might account
for the failure to detect it using western blotting in (28).
DISCUSSION
Structural rearrangements in eukaryotic termination
Formation of the ternary complex eRF1:eRF3:GTP and
its interactions with an array of binding partners such as
the pretermination complex and protein factors Upf1 and
PABP is a pivotal event in the convergence of translation
termination and NMD pathways. Our understanding
of the framework of interactions among the above-
mentioned components is critically dependent on determi-
nation of the network of possible mutually exclusive
complexes and interconvertion pathways among these,
backed up by structural information regarding the
complexes.
Currently we beneﬁt from structural insights into both
eRF1 and eRF3 from X-ray (25,38) and SAXS (39,40)
studies. The X-ray structure of full-length eRF1 com-
plexed with eRF3 lacking the G-domain has also been
determined (40). Taken together, the structural data
suggest that in the eRF3:eRF1 complex, eRF1 assumes
a bent conformation. However, available data on the
complex are either of low resolution (SAXS) or obtained
for the eRF3 lacking the G-domain, and it is the
G-domain (and GTP binding) that is crucial for the
function of the complex.
Biochemical data also suggest functionally important
structural ﬂexibility of eRF1 in the eRF1:eRF3 complex.
First, the existence of two diﬀerent conformations was
suggested by observed activation of peptide release upon
GTP hydrolysis on ribosome-bound eRF1:eRF3:GTP (9).
Diﬀerences in peptide release activation by GTP hydroly-
sis on eRF3 with mutant eRF1 variants on diﬀerent stop
codons indicate that the abovementioned conformational
changes might vary with each codon (41). Also, the exis-
tence of alternative eRF1 conformations was suggested in
ref. (4), where interactions between separate domains of
eRF1 with eRF3 were studied by ITC.
Our thermodynamical investigations of eRF3/eRF1/G
nucleotide interactions are also indicative of structural
rearrangements upon formation of the ternary complex
(see Figure 5 for a proposed model). One of the
parameters of the interactions we measured is change in
heat capacity, Cp, which is believed to reﬂect the degree
of structural rearrangement (35). Heat capacity changes
upon GDP binding both to eRF3 and eRF1:eRF3 are
relatively small ( 55 and  96cal mol
 1K
 1, respec-
tively), similar to what was observed for another
trGTPase we studied recently, EF-G ( 20cal mol
 1K
 1)
(7). This is expected, since GDP binding should not
promote structural rearrangements in the GTPase
(42). Formation of the eRF1:eRF3 complex has
moderate Cp ( 281cal mol
 1K
 1), although this is
Figure 4. Consensus and example sequence alignment of the extreme N-terminus of eRF3. Organism names are followed by NCBI GI numbers. The
sequence from Xenopus tropicalis was extended at the N-terminus by 15 amino acids, relative to the predicted protein product in Genbank following
the discovery of an alternate upstream start codon (mRNA GI number 62751651). The location of the PAM2-1 and PAM2-2 adjacent motifs are
indicated above the alignment. Seventy percent conservation consensus sequences were calculated using the Python script ConsensusFinder (GCA).
Uppercase letters indicate amino acids conserved in >70% of all examined sequences, and lowercase letters indicate a common amino acid substi-
tution group conserved in >70% of the sequences. A ‘.’ denotes a position that is not conserved in sequence, and gaps are denoted by ‘-’. Asterisks
below the Metazoa consensus sequence show residues that match the PAM2 motif, as represented in Pfam. The sites that were mutated are indicated
above the human sequence, with the letters indicating the amino acids present in the mutant forms. Red mutated postions: the PAM2-1 KAKA
mutant; Blue positions: the PAM2-2 AAKAA mutant; Blue underlined positions: the PAM2-2 AKA mutant.
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binding. According to X-ray data, the complex forma-
tion between truncated eRF3 and eRF1 buries 974A ˚ 2
(40), which is close to our estimates of 702–1040A ˚ 2 cor-
responding to Cp of  281cal mol
 1K
 1 (Table 3).
Complex formation between N-terminally deleted
eRF3Cp and eRF1 has similar Cp of  270cal 
mol
 1K
 1, suggesting that the N-domain does not inter-
fere with the formation of the complex, as was suggested
in ref. (26).
In the case of GTP binding to eRF1:eRF3, the Cp
change is colossal ( 1480cal mol
 1K
 1, Table 3), sug-
gesting major structural rearrangements with estimated
changes is SAA ranging from 3675 to 5444A ˚ 2 which
indicates an active role for GTP. This role has previously
been demonstrated in eRF1:eRF3-mediated termination
(9) and structural rearrangements in the eRF1:eRF3
complex have been proposed to take place during the
transition termination event (4,41).
The available X-ray reconstructions of eRF1:eRF3 were
done with the complex lacking the G-domain and SAXS
investigations were never carried only in the presence of
GTP (40). Thus, more detailed structural investigations
are required for clariﬁcation of the mechanistic details of
the GTP-induced rearmaments in eRF1:eRF3 complex.
Importantly, large-scale rearrangements are likely to be
hindered by the crystal packing, thus the soak-in
approach is likely to result in an artifactual structure not
representative of the solution conformation of the
complex. Therefore investigation by solution methods is
necessary.
PABP interactions with termination factors
Binding of PABP to both eRF3 and the eRF1:eRF3
complex had no eﬀect on GTP binding, suggesting that
in the presence of PABP formation of the eRF1:eRF3:
GTP complex is unperturbed (see Figure 5 for a
proposed model). GTP binding and hydrolysis by eRF3
is necessary for eﬃcient translation termination (9). PABP
has also been reported to have an activating role in termi-
nation (11,16), and our results demonstrate that both
Figure 5. Proposed model for eRF1:eRF3:PABP:G nucleotides interactions. eRF1 and eRF3 form a tight heterocomplex [(A and B), Kd=0.2mM].
Formation of the complex is characterized by moderate Cp change which gives a SAA estimate close to the experimental value [974A ˚ 2 (40), versus
estimated 702–1040A ˚ 2]. Binding of GDP to eRF1:eRF3 is characterized by a low Cp value, suggesting minor structural rearrangements (B–D),
whereas binding of GTP (B–F) is characterized by high Cp, suggesting major rearrangements (Table 3, Figure 3). Binding of PABP to the
eRF1:eRF3 complex does not interfere with GTP and GDP binding (C–E, C–G versus B–D, B–F, Table 1).
Nucleic AcidsResearch, 2010, Vol.38,No. 2 555of the activation signals (GTP and PABP binding) are
compatible.
The interaction between eRF3 and PABP is
characterized by a low stoichiometry of PABP binding
to eRF3 (0.50±0.06 PABP per eRF3). In the presence
of eRF1, the stoichiometry increases reaching 0.71±0.05
PABP per eRF3, suggesting possibility that the simultane-
ous presence of eRF1, eRF3 and PABP drives the system
towards formation of the eRF1:eRF3:PABP complex.
This eﬀect of PABP, i.e. stimulation of formation of the
termination-competent eRF1:eRF3:PABP:GTP complex
could be the corollary of PABP’s activating role in trans-
lation termination (11,16). However, one can not rule out
the possibility that this change in the stoichiometry could
be insigniﬁcant and reﬂect alterations in the experimental
system.
Despite having a conserved role in binding PABP
and other proteins, the N-domain is not universally
conserved in sequence across eukaryotes (17). However,
among groups of closely related organisms, regions of
homology are apparent. This includes the PAM2
minidomain, which we show is present across a wide dis-
tribution of metazoa, where it is comprised of 2 PAM2
motifs (Figure 4). The motifs are short and well-studied,
with x-ray structure (43), as well as calorimetric analysis
of PAM2 oligopeptide binding to PABP (23) available.
At 25 C, the peptide mimicking the two PAM2 motifs
of eRF3 binds to PABP with Kd 1.6mM, H 16kcal/
mol and TS 8.73kcal/mol, which is similar to our results
for the full-length eRF3 (Kd 0.7mM, H 30.3kcal/mol
and TS 21.9kcal/mol).
In silico analysis of the PAM2 minidomain identiﬁed
this motif in many proteins, including eRF3 from
several metazoan species (24). Our approach focused on
the architecture of this minidomain in eRF3, considering a
much larger representation of eukaryotes. In mammals,
there are two genes for eRF3, which diﬀer in their
N-terminal domains (44). These are referred to as eRF3a
(or GSPT1) and eRF3b (GSPT2). It is not clear how the
cellular roles of these versions diﬀer. Human eRF3a and
eRF3b are both functional in translation termination (45),
and mouse eRF3b can fully compensate for the eﬀects of
silenced eRF3a on termination (46). However, the two
versions diﬀer in tissue distribution and expression, with
eRF3a seemingly being the major factor in most cells as it
has the most widespread and abundant expression (46).
We ﬁnd that both eRF3a and eRF3b carry the PAM2-1
and PAM2-2 minidomains and therefore both appear
capable of PABP binding (Figure 4).
We identiﬁed conserved residues in the adjacent PAM2-
1 and PAM2-2 motifs in eRF3 (Figure 4), and tested the
importance of conserved residues by mutagenesis. We
created the PAM2-1 KAKA mutant which was earlier
reported to abolish the eRF3 binding to PABP (28), as
well as two mutants in the PAM2-2 motif. Unexpectedly,
the PAM2-1 KAKA mutant of eRF3 was able to bind
PABP, albeit with somewhat lower aﬃnity and dramati-
cally diﬀerent binding energetics (Table 1), while both
PAM2-2 mutants were completely deﬁcient in PABP
binding. This suggests that in human eRF3, PAM2-2 is
the primary site of PABP interaction. However, it is
possible that the primary binding site is diﬀerent in diﬀer-
ent organisms. In insects, only PAM2-2 is conserved
(Figure 4), while only PAM2-1 appears to be present in
the amoebozoan D. discoidium.
The interaction of eRF3 and PABP is the second of
two decision-making interactions that destine mRNA
for NMD, the ﬁrst being the eRF3 interaction with the
Exon-Junction Complex [for review see refs. (47,48)]. Our
detection of a motif in eRF3 indispensable for PABP
interaction (the AKA site of PAM2-2) provides a tool
for dissection of the connection between eRF3 activities
in translation termination and PABP-mediated NMD
pathways, using a point mutation in the PAM2-2 motif
to enable discrimination between the two NMD pathways:
the one mediated by EJC and the one mediated by
eRF3:PABP interactions.
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